Sanofi, Regeneron eczema drug gets FDA fast-track designation
November 20, 2014 at 01:47 AM EST
PARIS, Nov 20 (Reuters) - Sanofi and its U.S. partner Regeneron said on Thursday the U.S. Food and Drug Administration had designated their dupilumab drug as "breakthrough therapy" in the treatment of atopic dermatitis, a chronic form of eczema, granting the product a fast-track development and review process.